NHS National Framework Agreement for Lenalidomide, Pomalidomide and Thalidomide Supply

This is a national framework agreement (Offer reference: CM/PHG/24/5716) for the supply of three pharmaceutical products—Lenalidomide, Pomalidomide, and Thalidomide—to the NHS across three regional commissioning regions. The framework agreement runs from 1st June 2026 to 31st May 2028 across all regions (CESW covering Midlands and Southwest, NWLN covering Northwest and London North, and LSNE covering London South and Northeast), with options to extend for additional periods up to a maximum of 48 months. Suppliers should be established pharmaceutical manufacturers or distributors capable of meeting NHS quality, regulatory, and delivery standards for these specialist medicines used in cancer treatment.